Italia markets close in 6 hours 54 minutes

RXRX Jun 2024 3.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,20000,0000 (0,00%)
In data: 04:52PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,2000
Aperto0,2000
Denaro0,0000
Domanda0,5000
Prezzo d'esercizio3,00
Scadenza2024-06-21
Min-Max giorno0,2000 - 0,2000
Contratto - Min-MaxN/D
Volume6
Open Interest7
  • GlobeNewswire

    Recursion to Participate in Upcoming Investor Conferences

    SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Citi's 18th Annual BioPharma Conference – September 6-7, 2023Citi's Global Technology Conference – September 6-8, 2023Cantor Global Healthcare Conference – September 26-28, 2023 About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company lead

  • GlobeNewswire

    Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

    REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024.SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achi

  • GlobeNewswire

    Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds

    Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances were made possible by NVIDIA DGX Cloud supercomputing and the recent acquisition of Cyclica’s MatchMaker technology.SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced i